204 related articles for article (PubMed ID: 23419283)
1. Ras nanoclusters: a new drug target?
Cho KJ; Hancock JF
Small GTPases; 2013; 4(1):57-60. PubMed ID: 23419283
[TBL] [Abstract][Full Text] [Related]
2. Raf inhibitors target ras spatiotemporal dynamics.
Cho KJ; Kasai RS; Park JH; Chigurupati S; Heidorn SJ; van der Hoeven D; Plowman SJ; Kusumi A; Marais R; Hancock JF
Curr Biol; 2012 Jun; 22(11):945-55. PubMed ID: 22560614
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
[TBL] [Abstract][Full Text] [Related]
5. Electrostatic interactions positively regulate K-Ras nanocluster formation and function.
Plowman SJ; Ariotti N; Goodall A; Parton RG; Hancock JF
Mol Cell Biol; 2008 Jul; 28(13):4377-85. PubMed ID: 18458061
[TBL] [Abstract][Full Text] [Related]
6. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
8. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
[TBL] [Abstract][Full Text] [Related]
9. Drug targeting opportunities en route to Ras nanoclusters.
Pavic K; Chippalkatti R; Abankwa D
Adv Cancer Res; 2022; 153():63-99. PubMed ID: 35101236
[TBL] [Abstract][Full Text] [Related]
10. The Mystery of Rap1 Suppression of Oncogenic Ras.
Nussinov R; Jang H; Zhang M; Tsai CJ; Sablina AA
Trends Cancer; 2020 May; 6(5):369-379. PubMed ID: 32249186
[TBL] [Abstract][Full Text] [Related]
11. Clinical Translation of Combined MAPK and Autophagy Inhibition in
Lee JJ; Jain V; Amaravadi RK
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830283
[No Abstract] [Full Text] [Related]
12. FLIM-FRET Analysis of Ras Nanoclustering and Membrane-Anchorage.
Parkkola H; Siddiqui FA; Oetken-Lindholm C; Abankwa D
Methods Mol Biol; 2021; 2262():233-250. PubMed ID: 33977480
[TBL] [Abstract][Full Text] [Related]
13. Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters.
Zhou Y; Liang H; Rodkey T; Ariotti N; Parton RG; Hancock JF
Mol Cell Biol; 2014 Mar; 34(5):862-76. PubMed ID: 24366544
[TBL] [Abstract][Full Text] [Related]
14. Ras nanoclusters: Versatile lipid-based signaling platforms.
Zhou Y; Hancock JF
Biochim Biophys Acta; 2015 Apr; 1853(4):841-9. PubMed ID: 25234412
[TBL] [Abstract][Full Text] [Related]
15. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction.
Inder KL; Lau C; Loo D; Chaudhary N; Goodall A; Martin S; Jones A; van der Hoeven D; Parton RG; Hill MM; Hancock JF
J Biol Chem; 2009 Oct; 284(41):28410-28419. PubMed ID: 19661056
[TBL] [Abstract][Full Text] [Related]
17. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
18. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
19. H-Ras nanocluster stability regulates the magnitude of MAPK signal output.
Rotblat B; Belanis L; Liang H; Haklai R; Elad-Zefadia G; Hancock JF; Kloog Y; Plowman SJ
PLoS One; 2010 Aug; 5(8):e11991. PubMed ID: 20700538
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
